Spyre Therapeutics, Inc. (SYRE)

NASDAQ • Healthcare

$93.19

+$3.25 (+3.6%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$91.16

Day Range$90.48 - $95.27

Avg. Volume (3M)1.3M

Market Cap$8B

52 Week Range

$15.86$110.18

Next EarningsIn 30 daysNov 3, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

$90.4M

Net Income (TTM)

-$178.9M

EPS (TTM)

-$1.95

ROA (TTM)

-15.25%

Current Ratio

18.53

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+32.9%Q3 2025-$0.49

+80.3%Q4 2025-$0.15

-6.1%Q1 2026-$0.7

-12.1%Q2 2026-$0.74

+52.6%Q3 2026-$0.36

Nov 3

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Spyre Therapeutics, Inc. (SYRE) is set to report earnings on November 3, 2026. Consensus EPS is -$0.79. Historically, the company has beaten EPS in 5 of 8 most recent quarters, so traders may focus on whether results and commentary align with that pattern when the quarter is released.

View full earnings history

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a preclinical Biotechnology company listed on the NASDAQ Capital Market as SYRE that develops treatments for inflammatory bowel disease. The company focuses on drug candidates for people with ulcerative colitis and Crohn's disease, placing it in the biotech side of the healthcare sector.

Name

Spyre Therapeutics, Inc.

CEO

Cameron Turtle

Website

www.spyre.com

Industry

Healthcare

Year Founded

2013

Employees

125

Today's Snapshot

AI-generated

SYRE closed 3.6% higher at 93.19, while its sector was flat.

Trading Volume

Below 10d avg (1.3M)

vs S&P 500 Today

Outperforming Market

+2.85%

Updated: October 2, 2026 at 20:07 UTC

Technical Indicators

5 Buy3 Neutral0 Sell

SYRE displays constructive technical attributes with the price near 93.19, a positive CCI and multiple short- and medium-term moving averages trading above longer-term averages, consistent with an overall bullish alignment. Momentum measures are supportive while MACD is neutral-to-holding and ADX is low, indicating that the upmove lacks strong trend intensity. Volume-based OBV is positive, though ATR shows elevated volatility at roughly a 5% typical move. The classic pivot sits below the market and does not undermine the bullish bias. Technical takeaway: Buy.

All signals